Hepion Pharmaceuticals Announces Termination Of Merger Agreement With Pharma Two B Ltd.; Neither Party Will Be Required To Pay The Other A Termination Fee As A Result Of The Mutual Decision To Terminate The Agreement
Hepion Pharmaceuticals Announces Termination Of Merger Agreement With Pharma Two B Ltd.; Neither Party Will Be Required To Pay The Other A Termination Fee As A Result Of The Mutual Decision To Terminate The Agreement
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) (the "Company" or "Hepion"), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steatohepatitis ("NASH"), hepatocellular carcinoma ("HCC"), and other chronic liver diseases, today announced that it has entered into a termination agreement with Pharma Two B Ltd. which terminates the merger agreement between the two parties that was previously entered into on July 19, 2024.
Hepion Pharmaceuticals, Inc.（纳斯达克：HEPA）（"公司"或"Hepion"）是一家临床阶段的生物制药公司，曾开发用于治疗非酒精性脂肪性肝炎（"NASH"）、肝细胞癌（"HCC"）及其他慢性肝病的疗法。今天，公司宣布已与Pharma Two b Ltd.签署了一项终止协议，终止了双方于2024年7月19日签署的合并协议。
Neither party will be required to pay the other a termination fee as a result of the mutual decision to terminate the agreement.
双方因共同决定终止协议而无需支付对方终止费用。
Hepion also announced that its previously announced special meeting of its stockholders scheduled for December 12, 2024 has been cancelled and that it has withdrawn from consideration by its stockholders the proposals set forth in the Company's Definitive Proxy Statement on Form F-4 filed with the U.S. Securities and Exchange Commission on November 8, 2024.
Hepion还宣布，原定于2024年12月12日召开的股东特别会议已被取消，并且已撤回股东对公司在2024年11月8日向美国证券交易委员会提交的F-4号形式的最终委托书中所列提案的考虑。
